1
|
Crouzet S, Hostiou T, Khedime S, Rouviere O, Gelet A, Badet L. HIFU de rattrapage en 3e ligne pour les récidives locales après chirurgie et radiothérapie. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Michaud C, Codas-Duarte R, Matillon X, Crouzet S, Badet L, Fassi-Fehri H. One-year Functional Outcomes after Holmium Laser Enucleation of the Prostate (HoLEP): Introduction of a Composite Score (Hexafecta). Prog Urol 2021; 32:189-197. [PMID: 34656450 DOI: 10.1016/j.purol.2021.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 08/11/2021] [Accepted: 09/03/2021] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To compare the efficiency (micturition symptoms, continence, erection) and safety of Holmium Laser Enucleation of the Prostate (HoLEP) with a single composite score (the Hexafecta score) one year postprocedure. PATIENTS AND METHODS We conducted a single-center retrospective study including all patients who had undergone HoLEP for the treatment of benign prostate hyperplasia (BPH) between May 2013 and August 2017. Data were obtained preoperatively and at the 6- and 12-month visits. We also reported all 90-day complications. The Hexafecta score included 6 criteria: peak urine flow of at least 15ml/s, 30% reduction in International Prostate Symptoms Score (IPSS) score, quality of life via the IPSS less than 2, no incontinence (International Consultation Incontinence Questionnaire), no significant change in erectile function (International Index of Erectile Function), and no grade III or more complications according to the Clavien-Dindo classification. RESULTS Two hundred thirty-five patients were included, of whom 197 (83.8%) completed the 12-month visit. Complete data were available to assess the Hexafecta score for 178 of them (75.7%). Most of the missing data were for uroflowmetry and the erectile function assessment. Hundred three patients (58%) met all 6 criteria, while 45 (25%) met 5 of them. None were retreated for BPH in the follow-up period. The de novo incontinence rate was 4.1%. CONCLUSION The Hexafecta score is a simple, transversal method for comprehensively evaluating functional outcomes after HoLEP surgery. Such an evaluation could be used to compare other types of procedures for BPH treatment. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- C Michaud
- Hôpital Édouard-Herriot, Service d'Urologie et de la Transplantation, Hospices civils de Lyon, faculté de médecine Lyon Est, Université Lyon Claude Bernard, 5, place d'Arsonval, 69003 Lyon, France.
| | - R Codas-Duarte
- Hôpital Édouard-Herriot, Service d'Urologie et de la Transplantation, Hospices civils de Lyon, faculté de médecine Lyon Est, Université Lyon Claude Bernard, 5, place d'Arsonval, 69003 Lyon, France
| | - X Matillon
- Hôpital Édouard-Herriot, Service d'Urologie et de la Transplantation, Hospices civils de Lyon, faculté de médecine Lyon Est, Université Lyon Claude Bernard, 5, place d'Arsonval, 69003 Lyon, France
| | - S Crouzet
- Hôpital Édouard-Herriot, Service d'Urologie et de la Transplantation, Hospices civils de Lyon, faculté de médecine Lyon Est, Université Lyon Claude Bernard, 5, place d'Arsonval, 69003 Lyon, France
| | - L Badet
- Hôpital Édouard-Herriot, Service d'Urologie et de la Transplantation, Hospices civils de Lyon, faculté de médecine Lyon Est, Université Lyon Claude Bernard, 5, place d'Arsonval, 69003 Lyon, France
| | - H Fassi-Fehri
- Hôpital Édouard-Herriot, Service d'Urologie et de la Transplantation, Hospices civils de Lyon, faculté de médecine Lyon Est, Université Lyon Claude Bernard, 5, place d'Arsonval, 69003 Lyon, France
| |
Collapse
|
3
|
Crouzet S, Gelet A, Hostiou T, Rouviere O, Badet L, Regusci S, Martins M. Focal HIFU treatment of Apical lesion: Safety and oncological results. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01428-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Crouzet S, Pasticier G, Baco E, Rouviere O, Badet L, Gelet A. Focal HIFU treatment of radiorecurrent localized prostate cancer: Long term results. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01567-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
De Bayser H, Crouzet S, Badet L. Anastomose gonado-iliaque dans le cadre d’un nutcracker syndrome. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.08.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Hostiou T, Khedime S, Rouvière O, Lafon C, Badet L, Gelet A, Crouzet S. HIFU de sauvetage pour les récidives locales de cancer de prostate dans la loge de prostatectomie après chirurgie puis radiothérapie : résultats préliminaires. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Maoui M, Gonindard-Melodelima C, Chapet O, Colombel M, Ruffion A, Crouzet S, Rouvière O. Candidates to salvage therapy after external-beam radiotherapy of prostate cancer: Predictors of local recurrence volume and metastasis-free survival. Diagn Interv Imaging 2020; 102:93-100. [PMID: 32534903 DOI: 10.1016/j.diii.2020.05.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 05/13/2020] [Accepted: 05/19/2020] [Indexed: 12/23/2022]
Abstract
PURPOSE The purpose of this study was to assess the predictors of metastasis-free survival (MFS) and of the volume of the local recurrence in patients with rising prostate-specific antigen (PSA) serum level after radiotherapy for prostate cancer and referred for prostate magnetic resonance imaging (MRI) and biopsy in view of salvage treatment. MATERIALS AND METHODS A total of 132 consecutive men (median age, 70 years; IQR, 66-77 years) with rising PSA after prostate radiotherapy who underwent prostate MRI and biopsy in view of salvage treatment between January 2010 and July 2017 were retrospectively evaluated at a single center. MFS predictors were assessed with Cox models. Predictors of the volume of the local recurrence (number of invaded prostate sectors at biopsy) were assessed using Poisson regression among variables available at PSA relapse. RESULTS At multivariate analysis, an initial Gleason score≥8 (OR=7 [95% confidence interval (CI): 1.2-40]; P=0.03), a recent radiotherapy (OR=17 [95% CI: 3.9-72]; P<0.0001), the use of androgen deprivation therapy at PSA relapse (OR=12.5 [95% CI: 2.8-57]; P=0.001) and the number of invaded prostate sectors (OR=1.5 [95% CI: 1.1-2]; P=0.007) and maximum cancer core length (OR=0.7 [95%CI: 0.6-0.9]; P=0.002) at biopsy performed at PSA relapse were significant MFS predictors. The PSA level at relapse was significant independent predictor of the volume of local recurrence only when used as a continuous variable (P=0.0002) but not when dichotomized using the nadir+2 threshold (P=0.41). CONCLUSION Pathological and clinical factors can help predict MFS in patients with rising PSA after prostate radiotherapy and candidates to salvage treatment. The PSA level at relapse has strong influence on the local recurrence volume when used as a continuous variable.
Collapse
Affiliation(s)
- M Maoui
- Hospices Civils de Lyon, Department of Urinary and Vascular Radiology, Hôpital Édouard-Herriot, 69437 Lyon, France
| | - C Gonindard-Melodelima
- Université Joseph Fourier, Laboratoire d'Écologie Alpine, BP 53, 38041 Grenoble, France; CNRS, UMR 5553, BP 53, 38041 Grenoble, France
| | - O Chapet
- Hospices Civils de Lyon, Department of Radiation Oncology, Centre Hospitalier Lyon Sud, 69310 Pierre-Bénite, France
| | - M Colombel
- Hospices Civils de Lyon, Department of Urology, Hôpital Édouard-Herriot, 69437 Lyon, France; Université de Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, 69003 Lyon, France
| | - A Ruffion
- Hospices Civils de Lyon, Department of Urology, Centre Hospitalier Lyon Sud, 69310 Pierre-Bénite, France
| | - S Crouzet
- Hospices Civils de Lyon, Department of Urology, Hôpital Édouard-Herriot, 69437 Lyon, France; Université de Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, 69003 Lyon, France; Inserm, U1032, LabTau, 69003 Lyon, France
| | - O Rouvière
- Hospices Civils de Lyon, Department of Urinary and Vascular Radiology, Hôpital Édouard-Herriot, 69437 Lyon, France; Université de Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, 69003 Lyon, France; Inserm, U1032, LabTau, 69003 Lyon, France.
| |
Collapse
|
8
|
Seizilles de Mazancourt E, Crouzet S, Matillon X, Codas R, Fassi Fehri H, Abid N, Colombel M, Ye H, Hostiou T, Michaud C, Badet L. Auto-transplantation rénale entièrement robot-assistée pour syndrome de casse-noisettes. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Franquet Q, Terrier N, Badet L, Matillon X, Rambeaud J, Crouzet S, Long J, Lanchon C, Poncet D, Jouve T, Noble J, Grisard S, Lefrancq J, Overs C, Thuillier C, Rostaing L, Descotes J, Fiard G. Prélèvement de rein pour transplantation a donneur vivant, suites opératoires et évolution des donneurs. Évaluation bicentrique des pratiques sur 425 cas. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Delporte G, Olivier J, Ruffion A, Crouzet S, Cavillon C, Helfrich O, Leroy X, Villers A. [Evolution of the number of incident cases, stage and first treatments for prostate cancer in France between 2001 and 2016]. Prog Urol 2019; 29:108-115. [PMID: 30638756 DOI: 10.1016/j.purol.2018.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2018] [Revised: 10/14/2018] [Accepted: 12/12/2018] [Indexed: 10/27/2022]
Abstract
INTRODUCTION No studies of French hospital registries for prostate cancer (PCa) have been published since the 2012 USPSTF recommendations. MATERIAL This is a multicenter cohort study based on hospital data of prostate biopsies (PB) in 3 health centers between 2001 and 2016. The main objective is to describe the evolution of incident cases of PCa. The secondary objectives are to describe the number of cases per stage of PCa and the distribution of the first treatments. RESULTS In total, 11,491 PB series diagnosed 5927 cases of PCa. The median age was 67 [61-73] years and the median PSA was 7.8 [5.5-13] ng/mL. The number of cases increased until 2006 before decreasing from 2006 to 2013 and then stabilizing from 2013 to 2016. The proportion of incident cases was: (1) for the stable metastatic stage around 8 [7-10]%, (2) for cases with PSA<10 ng/mL increasing from 46% to 75% in 2010 down to 64% in 2016, (3) for the grade 1 group decreasing from 59% to 33 % between 2011 and 2016. The proportion of active surveillance treatment for low-risk cancers increased from 5 to 60% and surgery decreased from 73 to 33%. CONCLUSION The evolution of the incident cases showed a decrease from 2006 to 2013 and a stability until 2016. The number of cases with PSA<10 ng/mL decreased since 2010 and the proportion of the options of treatment by surveillance increased strongly to the detriment of the surgery for low risks. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- G Delporte
- Service d'urologie, université de Lille, CHU de Lille, 59000 Lille, France.
| | - J Olivier
- Service d'urologie, université de Lille, CHU de Lille, 59000 Lille, France
| | - A Ruffion
- Service d'urologie, centre hospitalier Lyon-sud, hospices civiles de Lyon, 69310 Pierre-Bénite, France
| | - S Crouzet
- Service d'urologie, hôpital Edouard-Herriot, hospices civiles de Lyon, 69003 Lyon, France
| | - C Cavillon
- Service d'urologie, polyclinique Saint-François-Saint-Antoine, 03100 Montluçon, France
| | - O Helfrich
- Service d'urologie, université de Lille, CHU de Lille, 59000 Lille, France
| | - X Leroy
- Service d'anatomo-pathologie, université de Lille, CHU de Lille, 59000 Lille, France
| | - A Villers
- Service d'urologie, université de Lille, CHU de Lille, 59000 Lille, France
| |
Collapse
|
11
|
Hostiou T, Gelet A, Rouvière O, Badet L, Crouzet S. Traitement par HIFU focal des cancers de prostate localisés : résultats oncologiques à moyen terme. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Arnouil N, Gelet A, Matillon X, Rouviere O, Colombel M, Ruffion A, Mège-Lechevallier F, Subtil F, Badet L, Crouzet S. [Focal HIFU vs robot-assisted total prostatectomy: Functionnal and oncologic outcomes at one year]. Prog Urol 2018; 28:603-610. [PMID: 30243461 DOI: 10.1016/j.purol.2018.07.285] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 07/25/2018] [Accepted: 07/31/2018] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To analyse the functional and oncologic outcomes at one year of focal therapy with HIFU compared with total prostatectomy in patients with localised prostate cancer (PCa). PATIENTS AND METHODS Retrospective and monocentric study from 2008 to 2014 comparing 2 cohorts of patients with localised PCa (T1/T2 clinical stage, Gleason score≤3+4=7 and PSA<15ng/mL), one treated by focal therapy (HIFU-F group), one by robot-assisted total prostatectomy (RATP group). Primary outcome was a trifecta defined as: absence of urinary incontinence, erectile function with sexual relations without treatment, negative PSA with negative surgical margins (RATP group) or negative biopsy cores (HIFU-F group). RESULTS The 53 patients included in the "HIFU-F" group and the 66 patients in the "RATP" group were similar in terms of preoperative PSA, D'Amico risk group, erectile function but were different in terms of age, prostatic volume, length of cancer, Gleason score. Complication rate was not different. In multivariate analyse with propensity score, "HIFU-F" group achieved a better trifecta score than "RATP" group (OR=8,3, p=0,005). CONCLUSION In case of low or intermediate risk localised PCa, "HIFU-F" group had better functional outcomes than initial learning curse "RATP" group, at one year. A long-term evaluation by a common endpoint is necessary to judge the oncological equivalence of both techniques. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- N Arnouil
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - A Gelet
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France
| | - X Matillon
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France; Inserm U1060, CarMeN Laboratory, université de Lyon, université Claude-Bernard Lyon 1, 69100 Villeurbanne, France
| | - O Rouviere
- Service de radiologie, hospices Civils de Lyon, hôpital Edouard-Herriot, Lyon, France
| | - M Colombel
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France
| | - A Ruffion
- Service d'urologie, hospices Civils de Lyon, centre hospitalier Lyon-Sud, Pierre Bénite, France
| | - F Mège-Lechevallier
- Service d'anatomopathologie, hospices Civils de Lyon, hôpital Edouard-Herriot, Lyon, France
| | - F Subtil
- Service de biostatistique, laboratoire de biométrie et biologie évolutive UMR 5558, hospices civils de Lyon, université de Lyon, université Lyon 1, CNRS, Villeurbanne, France
| | - L Badet
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France
| | - S Crouzet
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France
| |
Collapse
|
13
|
Baldini A, Fassi-Fehri H, Crouzet S, Badet L, Colombel M. L’application d’un programme de réhabilitation précoce (ERAS) améliore-t-elle les résultats périopératoires après cystectomie ? Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Matillon X, Gelet A, Rouvière O, Barret E, Sanchez-Salas R, Conort P, Pasticier G, Rischmann P, Villers A, Crouzet S. Étude IDITOP-3 : évaluation du traitement focal et multifocal du cancer de prostate localisé de la prostate par ultrasons focalisés à l’aide de l’appareil Focal One ® : résultats préliminaires. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Fassi-Fehri H, Codas Duarte R, Matillon X, Crouzet S, Collombel M, Abid N, Badet L. Étude de la continence après HoLEP : résultats à 6 mois. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
16
|
Abid N, Machon C, Dubourg L, Juillard L, Lemoine S, Badet L, Codas R, Fassi Fehri H, Crouzet S, Martin X. Retour sur un an de réunion multidisciplinaire autour de la lithiase urinaire. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Paganelli L, Baldini A, Fassi Fehri H, Crouzet S, Badet L, Colombel M. Mise en place d’un programme de réhabilitation précoce dans un service d’urologie : quelle courbe d’apprentissage ? Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Rouvière O, Puech P, Penna RR, Claudon M, Roy C, Lechevallier FM, Petrucci MD, Rabilloud M, Pethelaz AS, Chambardel MD, Magaud L, Cros F, Delongchamps NB, Boutier R, Bratan F, Brunelle S, Camparo P, Colin P, Correas J, Cornelis F, Cornud F, Descotes J, Eschwege P, Fiard G, Fendler J, Habchi H, Hallouin P, Khairoune A, Lang H, Lebras Y, Malavaud B, Moldovan P, Mottet N, Mozer P, Nevoux P, Pagnoux G, Pasticier G, Portalez D, Potiron E, Timsit M, Villers A, Walz J, Colombel M, Ruffion A, Crouzet S, Lemaitre L, Grenier N. Valeur ajoutée de l’IRM de prostate avant première série de biopsies : étude MRI-FIRST. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
19
|
Rouviere O, Puech P, Renard Penna R, Claudon M, Roy C, Mege Lechevallier F, Decaussin-Petrucci M, Rabilloud M, Schott Pethelaz A, Dubreuil Chambardel M, Magaud L, Cros F, Barry Delongchamps N, Boutier R, Bratan F, Brunelle S, Camparo P, Colin P, Correas J, Cornélis F, Cornud F, Descotes J, Eschwege P, Fiard G, Fendler J, Habchi H, Hallouin P, Khairoune A, Lang H, Lebras Y, Malavaud B, Moldovan P, Mottet N, Mozer P, Nevoux P, Pagnoux G, Pasticier G, Portalez D, Potiron E, Timsit MO, Villers A, Walz J, Colombel M, Ruffion A, Crouzet S, Lemaitre L, Grenier N. Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/s1569-9056(17)30558-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
Michaud C, fehri HF, duarte RC, Badet L, Crouzet S, Colombel M. Énucléation de la prostate par laser Holmium : évaluation des résultats à 6 mois à l’aide d’un score composite (Hexafecta). Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Hostiou T, Crouzet S, Tonoli-catez H, Badet L, Gelet A. Traitement HIFU de sauvetage pour récidive locale après curiethérapie : résultats fonctionnels et complications. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Lee J, Crouzet S, Soria J, Gal J, Melo-de-Lima C, Pommier P, Badet L, Gelet A. Radiothérapie externe de rattrapage (SRTE) après high intensity focused ultrasound (HIFU) versus HIFU de rattrapage (SHIFU) après radiothérapie externe (RTE) dans la récidive locale du cancer de prostate : analyse des résultats oncologiques et des complications. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Belot PY, Fassi-Fehri H, Colombel M, Matillon X, Crouzet S, Martin X, Abid N, Badet L. [The W-shaped ileal neobladder: Long term functional outcomes and health-related quality of life]. Prog Urol 2016; 26:367-74. [PMID: 27157921 DOI: 10.1016/j.purol.2016.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 02/26/2016] [Accepted: 03/22/2016] [Indexed: 10/21/2022]
Abstract
PURPOSE To evaluate functional outcomes and patients' health-related quality of life over ten years after a W-shaped ileal neobladder urinary diversion. PATIENTS AND METHODS From 1994 to 2004, 87 patients with bladder cancer underwent a cystoprostatectomy with a W-shaped ileal neobladder. Among them, 31 patients (35.6%) were evaluated. The average follow-up was 158months, average age was 72years. We assessed functional outcomes (use of protections, USP score, uroflowmetry, postvoid residual volume), overall health-related quality of life (SF-36 score), and specific urinary-related quality of life (Ditrovie scale). RESULTS Daytime continence was satisfactory in 29 patients (96.8%). Night-time continence was satisfactory in 27 patients (87.1%). Mean daytime continence, hyperactivity and dysuria scores of the USP were respectively 1.5/9, 3.2/21 and 2/9. Mean value of the maximum flow rate was 18mL/s for an average voiding volume of 324mL and an average postvoid residual volume of 70mL. The 8 dimensions of the SF-36 were all comparable with the French population's values. According to the Ditrovie scale whose average value was 1.83, the health-related quality of life was unchanged or little changed by urinary disorders in 28 patients (90.3%). CONCLUSIONS Our results suggest that voiding status and health-related quality of life remain satisfactory over ten years after an orthotopic ileal neobladder derivation. LEVEL OF EVIDENCE 5.
Collapse
Affiliation(s)
- P-Y Belot
- Service d'urologie et de transplantation, pavillon V, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - H Fassi-Fehri
- Service d'urologie et de transplantation, pavillon V, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - M Colombel
- Service d'urologie et de transplantation, pavillon V, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - X Matillon
- Service d'urologie et de transplantation, pavillon V, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - S Crouzet
- Service d'urologie et de transplantation, pavillon V, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - X Martin
- Service d'urologie et de transplantation, pavillon V, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - N Abid
- Service d'urologie et de transplantation, pavillon V, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - L Badet
- Service d'urologie et de transplantation, pavillon V, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| |
Collapse
|
24
|
Lalloué F, Ruffion A, Valette PJ, Crouzet S, Martin X, Rouvière O, Paparel P. Cryothérapie pour les tumeurs rénales : le début d’expérience de notre centre. Prog Urol 2016; 26:310-8. [DOI: 10.1016/j.purol.2016.02.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 01/17/2016] [Accepted: 02/23/2016] [Indexed: 01/20/2023]
|
25
|
Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol 2016; 34:1373-82. [PMID: 26892160 PMCID: PMC5026990 DOI: 10.1007/s00345-016-1782-x] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2015] [Accepted: 02/02/2016] [Indexed: 11/12/2022] Open
Abstract
PURPOSE To reach standardized terminology in focal therapy (FT) for prostate cancer (PCa). METHODS A four-stage modified Delphi consensus project was undertaken among a panel of international experts in the field of FT for PCa. Data on terminology in FT was collected from the panel by three rounds of online questionnaires. During a face-to-face meeting on June 21, 2015, attended by 38 experts, all data from the online rounds were reviewed and recommendations for definitions were formulated. RESULTS Consensus was attained on 23 of 27 topics; Targeted FT was defined as a lesion-based treatment strategy, treating all identified significant cancer foci; FT was generically defined as an anatomy-based (zonal) treatment strategy. Treatment failure due to the ablative energy inadequately destroying treated tissue is defined as ablation failure. In targeting failure the energy is not adequately applied to the tumor spatially and selection failure occurs when a patient was wrongfully selected for FT. No definition of biochemical recurrence can be recommended based on the current data. Important definitions for outcome measures are potency (minimum IIEF-5 score of 21), incontinence (new need for pads or leakage) and deterioration in urinary function (increase in IPSS >5 points). No agreement on the best quality of life tool was established, but UCLA-EPIC and EORTC-QLQ-30 were most commonly supported by the experts. A complete overview of statements is presented in the text. CONCLUSION Focal therapy is an emerging field of PCa therapeutics. Standardization of definitions helps to create comparable research results and facilitate clear communication in clinical practice.
Collapse
Affiliation(s)
- A W Postema
- Departments of Urology, AMC University Hospital, Amsterdam, The Netherlands.
| | - T M De Reijke
- Departments of Urology, AMC University Hospital, Amsterdam, The Netherlands
| | - O Ukimura
- USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.,Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - W Van den Bos
- Departments of Urology, AMC University Hospital, Amsterdam, The Netherlands
| | - A R Azzouzi
- Department of Urology, Angers University Hospital, Angers, France
| | - E Barret
- Department of Urology, Institut Montsouris, Université Paris Descartes, Paris, France
| | - D Baumunk
- Department of Urology, Magdeburg University Medical Center, Magdeburg, Germany
| | - A Blana
- Department of Urology, Fuerth Hospital, Fuerth, Germany
| | - A Bossi
- Department of Radiation Oncology, Gustave Roussy Institute, Villejuif, France
| | - M Brausi
- Department of Urology, Ospedale Civile Ramazzini, Carpi, Italy
| | - J A Coleman
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - S Crouzet
- Department of Urology and Transplantation, Edouard Herriot Hospital, Lyon, France
| | - J Dominguez-Escrig
- Department of Urology, Instituto Valenciano de Oncología, Valencia, Spain
| | - S Eggener
- Department of Urology, University of Chicago, Chicago, IL, USA
| | - R Ganzer
- Department of Urology, University of Leipzig, Leipzig, Germany
| | - S Ghai
- Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, Canada
| | - I S Gill
- USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - R T Gupta
- Departments of Radiology, Duke University Medical Center, Durham, NC, USA
| | - T O Henkel
- Urologische Praxis Dr. Henkel & Dr. Kahmann, Berlin, Germany
| | - M Hohenfellner
- Department of Urology, University of Heidelberg, Heidelberg, Germany
| | - J S Jones
- Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - F Kahmann
- Urologische Praxis Dr. Henkel & Dr. Kahmann, Berlin, Germany
| | - C Kastner
- CamPARI Prostate Cancer Clinic, Cancer Directorate, Cambridge University Hospitals Trust, Cambridge, UK
| | - K U Köhrmann
- Department of Urology, Theresien Krankenhaus Mannheim, Mannheim, Germany
| | - G Kovacs
- Interdisciplinary Brachytherapy Unit, University of Lübeck, Lübeck, Germany
| | - R Miano
- Division of Urology, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
| | - R J van Moorselaar
- Department of Urology, Free University Medical Centre, Amsterdam, The Netherlands
| | - N Mottet
- Department of Urology, University Hospital St Etienne, Saint-Étienne, France
| | - L Osorio
- Department of Urology, Porto Hospital Centre, Porto, Portugal
| | - B R Pieters
- Departments of Radiation Oncology, AMC University Hospital, Amsterdam, The Netherlands
| | - T J Polascik
- Departments of Surgery, Duke University Medical Center, Durham, NC, USA
| | - A R Rastinehad
- Department of Urology, Hofstra North Shore-Lij, Hofstra University, Hempstead, NY, USA
| | - G Salomon
- Martini-Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - R Sanchez-Salas
- Department of Urology, Institut Montsouris, Université Paris Descartes, Paris, France
| | - M Schostak
- Department of Urology, Magdeburg University Medical Center, Magdeburg, Germany
| | - L Sentker
- Urologische Gemeinschaftspraxis, Sinsheim, Germany
| | - K J Tay
- Departments of Surgery, Duke University Medical Center, Durham, NC, USA
| | - I M Varkarakis
- 2nd Department of Urology, Athens Medical University, University of Athens, Athens, Greece
| | - A Villers
- Department of Urology, Lille University Medical Center, Lille, France
| | - J Walz
- Department of Urology, Institut Paoli-Calmettes, Marseille, France
| | - J J De la Rosette
- Departments of Urology, AMC University Hospital, Amsterdam, The Netherlands
| |
Collapse
|
26
|
Codas R, Badet L, Ravier E, Abid N, Crouzet S, Colombel M, Martin X, Fassi-fehri H. Vapoénucléation prostatique au laser thulium selon « la mushroom technique ». Prog Urol 2015; 25:864-5. [DOI: 10.1016/j.purol.2015.08.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Pierrard V, Abid N, Albert G, Codas R, Fassi-Fehri H, Martin X, Badet L, Crouzet S. L’HIFU : une option dans le traitement des récidives locales des cancers prostatiques après chirurgie et radiothérapie. Prog Urol 2015; 25:835. [DOI: 10.1016/j.purol.2015.08.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
28
|
Crouzet S, Rouviere O, Bratan F, Colombel M, Badet L, Tonoli-Catez H, Gelet A. Traitement focal par HIFU des récidives locales des cancers de prostate initialement traités par radiothérapie. Prog Urol 2015; 25:835-6. [DOI: 10.1016/j.purol.2015.08.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Crouzet S, Rouviere O, Bratn F, Tonoli-Catez H, Cros F, Badet L, Gelet A. Traitements focal des adénocarcinomes prostatiques par HIFU : résultats oncologiques et fonctionnels. Prog Urol 2015; 25:835. [DOI: 10.1016/j.purol.2015.08.237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
30
|
Crouzet S, Rouviere O, Bratan F, Colombel M, Badet L, Chapelon J, Tonoli-Catez H. Traitement HIFU de sauvetage pour récidive locale après curiethérapie : résultats carcinologiques et fonctionnels. Prog Urol 2015; 25:836. [DOI: 10.1016/j.purol.2015.08.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Helfrich O, Crouzet S, Ruffion A, Houlgatte A, Cavillon C, Gerard C, Villers A. [Evolution of the number of incident cases of prostate cancer in France from 2001 to 2012 from 5 hospital centers]. Prog Urol 2014; 25:147-56. [PMID: 25481672 DOI: 10.1016/j.purol.2014.10.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Revised: 09/25/2014] [Accepted: 10/06/2014] [Indexed: 11/25/2022]
Abstract
OBJECTIVES The main objective is the study of the evolution of the number of incident cases of prostate cancer in France from 2001 to 2012 from 5 hospital centers of urology. The secondary objective is to describe the characteristics of the incident cases and to compare them to those of the patients of the national registers of cancer for the period. MATERIAL AND METHODS Prospective observational multicentric study from 01/01/2001 to 31/12/2012 of databases in 5 French, public and private hospital centers of urology. The inclusive centers were selected outside departments with cancer register. The collected data were the prostatic biopsies performed in every center and the number of positive biopsies. The biopsies in cases of already known cancer and in re-evaluation were excluded. The data of age and stage (PSA and Gleason grade) were collected. The estimation of the incidence standardized in France is established after a period of observation of 3 years. The data updated in 2009 show a peak of incidence in 2005 then a decrease from 2006 (64,518 cases) until 2009 (53,465 cases). The median age in the diagnosis was of 70 years in 2005. RESULTS Overall, 18,392 prostatic biopsies were included in the analysis. The average rate of positive biopsies was stable over the period 51.41% (IQR 0,02). The total number of cases of positive biopsies increased from 2001 to 2007 (482 cases in 1028 cases) in 2007, then decreased from 2008 to 2012 (649 cases). There was no difference in this variation between the centers. The median age in the diagnosis was of 70 years (EIQ=1.5) in 2001 and 68 years (EIQ=2.75) in 2012. PSA at diagnosis was<10ng/mL in 65% of cases and 10 to 20ng/mL in 22% of cases in 2012. The population of patients of the study differed significantly from that of FRANCIM on the distribution by age ranges (year 2005, P<0.0001 and year 2009, P<0.001), which explains the gap of one year (on 2007 instead of 2006) of the peak of incidental cases. CONCLUSION The evolution of the number of incidental cases of prostate cancer in France from 2001 to 2012 from hospital data of 5 centers are similar to those of the network of registers representative of the French population. This observed evolution represents data available for cancer registers to estimate incidence variation between 2 publications. LEVEL OF EVIDENCE 4.
Collapse
Affiliation(s)
- O Helfrich
- Service d'urologie, université Lille-Nord-de-France, CHU de Lille, 59000 Lille, France
| | - S Crouzet
- Centre hospitalier Lyon-sud, hospices civiles de Lyon, 69310 Lyon, France
| | - A Ruffion
- Hôpital Edouard-Herriot, hospices civiles de Lyon, 69003 Lyon, France
| | - A Houlgatte
- Hôpital d'instruction des Armées Val-de-Grâce, 75005 Paris, France
| | - C Cavillon
- Polyclinique Saint-François - Saint-Antoine, 03100 Montluçon, France
| | - C Gerard
- Clinique Océane, 56000 Vannes, France; 6 Kyoto Prefectural University of Medicine, 602-0841 Kyoto, Japon
| | - A Villers
- Service d'urologie, université Lille-Nord-de-France, CHU de Lille, 59000 Lille, France.
| |
Collapse
|
32
|
Ricci E, Cai H, Martin X, Crouzet S, Colombel M. Étude coût-efficacité de la prostatectomie par laparoscopie robot assistée versus prostatectomie par laparoscopie : analyse de cohortes appariées, sur la période périopératoire et à 2 ans de suivi. Prog Urol 2014; 24:866. [DOI: 10.1016/j.purol.2014.08.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
33
|
Crouzet S, Gelet A, Tonoli Catez H, Villers A, Pasticier G, Bugel H, Petit J, Jung J, Bondil P, Toledano H, Rouviere O, Rischmann P. Traitement des adénocarcinomes prostatiques limité à un lobe par hémiablation HIFU (étude AFU) sur 110 patients. Prog Urol 2014; 24:859. [DOI: 10.1016/j.purol.2014.08.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Crouzet S, Tonoli Catez H, Rouviere O, Mege Lechevalier F, Martin X, Gelet A. Traitement focal des adénocarcinomes prostatique localisés par HIFU focal : l’échographie de contraste reflète-t-elle bien la zone traitée ? Prog Urol 2014; 24:859. [DOI: 10.1016/j.purol.2014.08.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
35
|
Bakrim A, Ngunjiri J, Crouzet S, Guibout L, Balducci C, Girault JP, Lafont R. Ecdysteroid Profiles of Two Ajuga species, A. iva and A. remota. Nat Prod Commun 2014. [DOI: 10.1177/1934578x1400900804] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Phytoecdysteroids are plant analogues of insect moulting hormones and are used by plants to repel or disturb phytophagous insects. They are also active on mammals and present in many plants used in traditional medicine. The Ajuga genus contains several such species, which occur in various pharmacopoeias. We report the isolation and identification of major and minor ecdysteroids present in two Ajuga species, A. iva and A. remota, both of which are used as medicinal plants in Africa. Three minor ecdysteroids (abutasterone, ponasterone A and sidisterone) have been found for the first time in the Ajuga genus.
Collapse
Affiliation(s)
- Ahmed Bakrim
- Sorbonne Universités, Université Pierre et Marie Curie, IBPS-BIOSIPE, 7 Quai Saint Bernard, Case Courrier 29, 75252 Paris Cedex 05, France
- Département de Géographie-Biologie-Géologie (GBG), Faculté Polydisciplinaire de Khouribga, Université Hassan I, Morocco
| | | | - Sophie Crouzet
- Sorbonne Universités, Université Pierre et Marie Curie, IBPS-BIOSIPE, 7 Quai Saint Bernard, Case Courrier 29, 75252 Paris Cedex 05, France
| | - Louis Guibout
- Sorbonne Universités, Université Pierre et Marie Curie, IBPS-BIOSIPE, 7 Quai Saint Bernard, Case Courrier 29, 75252 Paris Cedex 05, France
- Institut Biophytis, F-93230 Romainville, France
| | | | - Jean-Pierre Girault
- Université Paris Descartes, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS UMR 8601, 45 rue des Saints-Pères, F-75270 Paris Cedex 06, France
| | - René Lafont
- Sorbonne Universités, Université Pierre et Marie Curie, IBPS-BIOSIPE, 7 Quai Saint Bernard, Case Courrier 29, 75252 Paris Cedex 05, France
| |
Collapse
|
36
|
Bakrim A, Ngunjiri J, Crouzet S, Guibout L, Balducci C, Girault JP, Lafont R. Ecdysteroid profiles of two Ajuga species, A. iva and A. remota. Nat Prod Commun 2014; 9:1069-1074. [PMID: 25233576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023] Open
Abstract
Phytoecdysteroids are plant analogues of insect moulting hormones and are used by plants to repel or disturb phytophagous insects. They are also active on mammals and present in many plants used in traditional medicine. The Ajuga genus contains several such species, which occur in various pharmacopoeias. We report the isolation and identification of major and minor ecdysteroids present in two Ajuga species, A. iva and A. remota, both of which are used as medicinal plants in Africa. Three minor ecdysteroids (abutasterone, ponasterone A and sidisterone) have been found for the first time in the Ajuga genus.
Collapse
|
37
|
Habchi H, Bratan F, Paye A, Pagnoux G, Sanzalone T, Mège-Lechevallier F, Crouzet S, Colombel M, Rabilloud M, Rouvière O. Value of prostate multiparametric magnetic resonance imaging for predicting biopsy results in first or repeat biopsy. Clin Radiol 2014; 69:e120-8. [DOI: 10.1016/j.crad.2013.10.018] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2013] [Revised: 10/13/2013] [Accepted: 10/30/2013] [Indexed: 12/31/2022]
|
38
|
Crouzet S, Meyer V, Matillon X, Forest S, Colombel M, Badet L, Martin X. Première néphrectomie partielle robotique avec utilisation du système Single-Site. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Crouzet S, Marechal J, Colombel M, Rouvière O, Chapelon J, Rabilloud M, Belot A, Mège-Lechevallier F, Bouvier R, Tonoli-Catez H, Martin X, Gelet A. Comparaison par paires appariées de la prostatectomie radicale et de l’Ablatherm® (HIFU) dans le traitement du cancer localisé de la prostate. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Helfrich O, Crouzet S, Ruffion A, Houlgatte A, Cavillon C, Gerard C, Villers A. Étude des variations du nombre de cas incidents des cancers de prostate en France à partir de 5 centres. Extrapolation nationale. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
41
|
Forest S, Glachant S, Crouzet S, Fassi-Fehri H, Colombel M, Gelet A. Traitement des fistules urètro-rectale et prostato-rectale par voie trans-anorectale de York Mason : expérience monocentrique sur 17 patients consécutifs. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Codas R, Ravier E, Crouzet S, Abid N, Colombel M, Badet L, Martin X, Fassi-Fehri H. Complications de l’énucléation prostatique et de la morcellation pour HBP par laser thulium. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
Adam E, Martin L, Martin X, Badet L, Haber G, Crouzet S. Prélèvement de rein sur donneur vivant par LESS : technique et résultats. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Soria J, Crouzet S, Ardiet J, Chapet O, Pommier P, Tonoli-Catez H, Martin X, Gelet A. Radiothérapie de sauvetage des récidives locales après traitement initial par HIFU : évaluation de l’efficacité et de la tolérance chez 221 patients. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
Ravier E, Fassi-Fehri H, Gelet A, Abid N, Crouzet S, Martin X. Complications du sphincter artificiel urinaire AMS 800 chez les patients avec versus sans antécédents de radiothérapie. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
Ripert T, Crouzet S, Ploussard G, De La Taille A, Robert G. Mécanismes de résistance aux in hibiteurs de CYP17A1 dans le cancer de la prostate résistant à la castration. Prog Urol 2013; 23 Suppl 1:S16-22. [DOI: 10.1016/s1166-7087(13)70042-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Sofer I, Lee KR, Sailamul P, Crouzet S, Serre T. Understanding the nature of the visual representations underlying rapid categorization tasks. J Vis 2013. [DOI: 10.1167/13.9.658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
48
|
Forest S, Polo G, Habchi H, Codas R, Abid N, Fassi-fehri H, Colombel M, Martin X, Badet L, Crouzet S. Néphrectomie partielle cœlioscopique : nouvelle technique de clampage parenchymateux. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Crouzet S, Rouvière O, Chapelon JY, Mège-lechevallier F, Abid N, Martin X, Gelet A. HIFU de sauvetage pour récidive locale après curiethérapie. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Matillon X, Crouzet S, Murat F, Cherasse A, Gelet A, Martin X. Cryothérapie de rattrapage pour récidive de cancer de prostate après radiothérapie externe. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|